Shockwave Medical to Announce Late-Breaking Results of Study of Novel Lithoplasty System for the Treatment of Peripheral Artery Disease

FREMONT, Calif.--()--Shockwave Medical, a pioneer in the treatment of peripheral and coronary vascular disease, today announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty™ balloon catheters for the treatment of peripheral artery disease, at the Vascular Interventional Advances (VIVA) Annual Conference taking place November 4-7 in Las Vegas, Nevada.

Results of DISRUPT PAD will be presented by study principal investigator Marianne Brodmann, M.D., of the Medical University of Graz, Austria, on Wednesday, November 5, during the Late-Breaking Trials Session taking place 8:10 to 9:34 a.m. PT.

In advanced vascular disease, atherosclerosis becomes calcified deep inside the vessel walls, limiting blood flow. These deposits are difficult to treat because they limit the effectiveness of current endovascular devices, making today’s interventions challenging and prone to both procedural and long-term failure. Lithoplasty is a novel balloon-based technology that utilizes integrated lithotripsy, a pulsatile mechanical energy commonly used to break up kidney stones, to disrupt both superficial and deep calcium and normalize vessel wall compliance prior to low-pressure balloon dilatation. Lithoplasty is designed to be naturally gentle to soft tissue (non-diseased portions of the vessel) while remaining hard on calcium, the tissue that limits vessel expansion and the effectiveness of current technologies.

About Shockwave’s Lithoplasty System

Unlike current devices that treat only superficial calcium, Shockwave’s Lithoplasty system is designed to be effective on all types of calcium, including deep – the type known to limit vessel expansion. Delivered on a standard balloon catheter platform, Lithoplasty combines the calcium disrupting power of lithotripsy with the familiarity and simplicity of a balloon in a single enabling device. Lithoplasty applies a brief series of powerful mechanical pulses designed to safely travel through soft tissue, disrupt and pre-treat calcium. The integrated balloon is then dilated at low pressures to expand the lesion evenly, potentially minimizing acute soft tissue injury that could lead to the need for additional interventional treatments, or long-term restenosis (re-blockage).

About Shockwave Medical

Shockwave Medical, based in Fremont, Calif., is pioneering Lithoplasty™ technology, a promising breakthrough for the treatment of peripheral and coronary vascular disease and aortic stenosis. Delivered on a standard balloon catheter platform, Lithoplasty combines the calcium disrupting power of lithotripsy with the familiarity and simplicity of a balloon in a single enabling device. For more information, visit www.shockwavemedical.com.

Contacts

Shockwave Medical
Media Contact:
Nicole Osmer, 650-454-0504
nicole@nicoleosmer.com

Contacts

Shockwave Medical
Media Contact:
Nicole Osmer, 650-454-0504
nicole@nicoleosmer.com